<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03312855</url>
  </required_header>
  <id_info>
    <org_study_id>Revacept/CAD/02</org_study_id>
    <nct_id>NCT03312855</nct_id>
  </id_info>
  <brief_title>A Phase II Randomised Double-blind, Placebo-controlled Study of Revacept in Patients With Stable Coronary Artery Disease</brief_title>
  <official_title>Revacept, a Novel Inhibitor of Platelet Adhesion in Patients With Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Interventions: a Phase II, Multicentre, Randomised, Double-blind and Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AdvanceCor GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to evaluate the efficacy and safety of treatment with 2 doses (80 and
      160 mg) of Revacept versus placebo in patients with stable coronary artery disease undergoing
      PCI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Revacept is a protein that is made up of an Fc fragment (&quot;fragment crystallisable&quot;) fused to
      the GPVI receptor (the endogenous platelet collagen receptor). Consequently, Revacept binds
      to its ligand (collagen) on atherosclerotic plaques preventing circulating thrombocytes from
      binding to collagen exposed by the injured plaque. All this is achieved without affecting
      systemic hemostasis.

      Thus, blocking of GPVI-dependent pathways by interfering with vascular collagen sites is
      commonly seen as an attractive target for an anti-platelet therapy of atherosclerotic
      diseases.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2017</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>with 2 doses (80 and 160 mg) of Revacept versus placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary endpoint-composite endpoint of death and myocardial injury</measure>
    <time_frame>within 48 hours from randomisation</time_frame>
    <description>A composite endpoint of death or myocardial injury (defined as increase in cardiac biomarker - high sensitivity cardiac troponin of at least 5 times the upper limit of norm (ULN) within 48 hours from randomisation).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>within 30 days after randomisation</time_frame>
    <description>All cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>within 30 days after randomisation</time_frame>
    <description>Myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCI-related (type 4) myocardial infarction</measure>
    <time_frame>within 30 days after randomisation</time_frame>
    <description>PCI-related (type 4) myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite stent thrombosis</measure>
    <time_frame>within 30 days after randomisation</time_frame>
    <description>Definite stent thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urgent coronary revascularization</measure>
    <time_frame>within 30 days after randomisation</time_frame>
    <description>Urgent coronary revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>within 30 days after randomisation</time_frame>
    <description>Stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak potprocedural high-sensitivity troponin level</measure>
    <time_frame>within 30 days after randomisation</time_frame>
    <description>Peak potprocedural high-sensitivity troponin level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding class 2 or higher according to Bleeding Academic Research Consortium (BARC) criteria (safety endpoint)</measure>
    <time_frame>within 30 days after randomisation</time_frame>
    <description>Bleeding class 2 or higher according to Bleeding Academic Research Consortium (BARC) criteria (safety endpoint)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">332</enrollment>
  <condition>Stable Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Revacept 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose, intravenous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Revacept 160 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose, intravenous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose, intravenous</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Revacept 80 mg</intervention_name>
    <description>single dose, intravenous application of 80 mg Revacept</description>
    <arm_group_label>Revacept 80 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Revacept 160 mg</intervention_name>
    <description>single dose, intravenous application of 180 mg Revacept</description>
    <arm_group_label>Revacept 160 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single dose, intravenous application of Placebo solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent

          -  Men and women &gt;18 years of age

          -  Diagnosis: Clinically stable coronary artery disease

          -  Angiographic evidence of coronary artery disease

          -  Indication for PCI

        Exclusion Criteria:

          -  WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for
             up to 4 weeks after receiving investigational product.

          -  Women who are pregnant or breastfeeding or are planning pregnancy during course of
             trial

          -  Women with a positive pregnancy test on enrolment or prior to investigational product
             administration.

          -  History of hypersensitivity, contraindication or serious adverse reaction to any
             component of the study drug (GPVI-Fc, sucrose, mannitol), acetylsalicylic acid or
             clopidogrel

          -  History of bleeding diathesis or active bleeding within the last 30 days

          -  Recent intracerebral haemorrhage or trauma within the last 3 months

          -  Thrombocytopenia (platelet count &lt;30000/mm3) at screening

          -  Sustained hypertension (systolic BP &gt;179mmHg or diastolic BP &gt;109mmHg) at screening

          -  Renal failure (estimated glomerular filtration rate &lt; 30ml/min and/or dialysis)

          -  Severe systemic disease, such as known malignancies or other comorbid conditions with
             life expectancy less than one year that may result in protocol non-compliance

          -  Unable to provide informed consent (e.g. severe dementia, or psychosis)

          -  Current severe liver dysfunction (transaminase level &gt;5-fold the upper normal range
             limit)

          -  Patients with an indication for anticoagulant therapy

          -  Participation in any other clinical interventional trial (drug/device) within less
             than 30 days prior to screening

          -  Any other contraindication to perform PCI

          -  Any planned additional PCI or surgery within 30 days after randomization

          -  Suspected poor capability to follow instructions and cooperate

          -  Prisoners or subjects who are involuntarily incarcerated

          -  Subjects who are compulsorily detained for treatment of either a psychiatric or
             physical illness (e.g. infectious disease)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adnan Kastrati, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum München</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steffen Massberg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Klinikum der Universität München</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefanie Schuepke, MD</last_name>
    <role>Study Director</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adnan Kastrati, MD</last_name>
    <phone>+49891218</phone>
    <phone_ext>4578</phone_ext>
    <email>kastrati@dhm.mhn.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marion Janisch, MD</last_name>
    <phone>+49891218</phone>
    <phone_ext>1547</phone_ext>
    <email>janischm@dhm.mhn.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Deutsches Herzzentrum München</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adnan Kastrati, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Janisch Marion, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Adnan Kastrati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katharina Mayer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt, Medizinische Klinik III, Kardiologie</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mariuca Vasa-Nicotera, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Andreas Zeiher, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Mariuca Vasa-Nicotera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Zeiher, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universtätsmedizin Mainz, Zentrum für Kardiologie/Kardiologie I</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tommaso Gori, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Thomas Münzel, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Tommaso Gori, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Münzel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München, Medizinische Klinik und Poliklinik I</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Sibbing, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Gross Lisa, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dirk Sibbing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lisa Gross, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Danny Kupka, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar, I. Medizinische Klinik und Poliklinik</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karl-Ludwig Laugwitz, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Rainer Okrojek, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Karl-Ludwig Laugwitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rainer Okrojek, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg, Klinik und Poliklinik für Innere Medizin II</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcus Fischer, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Christoph Birner, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Marcus Fischer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Birner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2017</study_first_submitted>
  <study_first_submitted_qc>October 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2017</study_first_posted>
  <last_update_submitted>November 20, 2017</last_update_submitted>
  <last_update_submitted_qc>November 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <keyword>platelet inhibition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

